By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen has a strong track record of building strategic partnerships with health systems around the world.
These collaborations are essential for our mission “to serve patients”, enhancing healthcare and improving patient outcomes. Our partnerships cover a broad range of initiatives, emphasising innovative solutions to healthcare challenges.
We are a responsible biotechnology company that aims to create value by addressing health issues that affect society the most and have the most room for improvement. We want to make a difference by investing in preventing serious health problems, not just treating them when they happen. That's why we work with the NHS to develop new ways of caring for patients.
We have the time, resources and drive to invest in understanding the healthcare policies, political, and economic forces and bureaucratic barriers that can get in the way of keeping people healthy.
With the patient at the heart, Amgen uses data and experience to examine environmental factors at local, regional, and national levels to test hypotheses and develop solutions that can show meaningful improvement.
Through initiatives involving patient identification, medicines optimisation, service redesign, and more, our aim is to create value for all parties on a fair basis – value for Amgen, the health system, and most importantly, for patients.
Please refer to our page on Transparency for more information about our collaborative working and joint working projects and transfers of value.
Demonstrating a comprehensive approach to risk prediction and prevention for cardiovascular disease (CVD) patients.
